Printer Friendly

New drug may benefit liposarcoma patients.

The Food and Drag Administration has approved Eisai Inc.'s Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma that cannot be removed by surgery or is at an advanced stage (metastatic). According to the regulatory agency, this treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. "Halaven is the first drug approved for patients with liposarcoma that has demonstrated an improvement in survival time," commented Richard Pazdur, director of the office of hematology and oncology products in the FDA's Center for Drug Evaluation and Research (CDER). "The clinical trial data the FDA reviewed indicates that Halaven increased overall survival by approximately seven months, offering patients a clinically meaningful drug."

COPYRIGHT 2016 Racher Press, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Rx Update
Publication:Chain Drug Review
Date:Feb 22, 2016
Previous Article:Independents look to uphold service edge.
Next Article:Merck's Zepatier approved.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters